Artelo BiosciencesARTL +1.37%31 Return-on-Tangible-Asset is -210.52% as of Mar. 2026. GuruFocus rates ARTL with a GF Score™ of 31/100. The stock has 2 warning signs investors should review. Among 1,418 Biotechnology companies, Artelo Biosciences ranks worse than 96.05% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Artelo Biosciences's annualizedNet Income for the quarter that ended in Mar. 2026 was $-11.83 Mil. Artelo Biosciences's average total tangible assets for the quarter that ended in Mar. 2026 was $5.62 Mil. Therefore, Artelo Biosciences's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was -210.52%.
The historical rank and industry rank for Artelo Biosciences's Return-on-Tangible-Asset or its related term are showing as below:
ARTL'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -752.94 Med: -126.16 Max: -63.21
Current: -390
During the past 12 years, Artelo Biosciences's highest Return-on-Tangible-Asset was -63.21%. The lowest was -752.94%. And the median was -126.16%.
ARTL's Return-on-Tangible-Asset is ranked worse than 96.05% of 1418
companies
in the Biotechnology industry
Industry Median: -35.915
vs ARTL: -390.00
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Artelo Biosciences Return-on-Tangible-Asset Related Terms
Artelo Biosciences Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Artelo Biosciences's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ARTL vs REVB, MTNB, ONCO: Return-on-Tangible-Asset Comparison
For the Biotechnology subindustry, Artelo Biosciences's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Artelo Biosciences Return-on-Tangible-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Artelo Biosciences's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Artelo Biosciences's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of -210.52% mean?
Artelo Biosciences (ARTL) has a Return-on-Tangible-Asset of -210.52% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Artelo Biosciences and its competitors. According to the industry distribution chart, Artelo Biosciences ranks #1362 out of 1418 companies in the Biotechnology industry, placing it in the top 96.1%.
Is Artelo Biosciences' Return-on-Tangible-Asset too high?
Artelo Biosciences' current Return-on-Tangible-Asset is -210.52%. Based on the distribution chart, Artelo Biosciences ranks #1362 out of 1418 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Artelo Biosciences has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Artelo Biosciences' Return-on-Tangible-Asset compare to REVB and MTNB?
According to the Biotechnology industry distribution chart, Artelo Biosciences ranks #1362 out of 1418 companies for Return-on-Tangible-Asset. This places Artelo Biosciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Biotechnology company?
A good Return-on-Tangible-Asset depends on the Biotechnology industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Artelo Biosciences and its competitors. Artelo Biosciences's current Return-on-Tangible-Asset is -210.52%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Artelo Biosciences stock overvalued right now?
Artelo Biosciences (ARTL) has a current Return-on-Tangible-Asset of -210.52%. The current Return-on-Tangible-Asset is -210.52%. Artelo Biosciences' overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Artelo Biosciences (ARTL), the current Return-on-Tangible-Asset is -210.52% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.
31GF Score
Get the complete analysis for ARTL
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ARTL has been successfully added to your 
